cobas® eplex bcid panels Search Results


90
GenMark Diagnostics cobas eplex bcid-fp
Commercial molecular assays.
Cobas Eplex Bcid Fp, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cobas%C2%AE+eplex+bcid+panels/cobas+++eplex+bcid+fp/pmc11763552-33-0-3
Average 90 stars, based on 1 article reviews
cobas eplex bcid-fp - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
BioFire Defense eplex bcid ruo panels
Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of <t>ePlex</t> <t>BCID</t> panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID <t>RUO</t> or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).
Eplex Bcid Ruo Panels, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cobas%C2%AE+eplex+bcid+panels/eplex+bcid+ruo+panels/pmc08370220-103-2-10
Average 90 stars, based on 1 article reviews
eplex bcid ruo panels - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
BioFire Defense filmarray blood culture id (bcid) panel
Comparison of RDT platforms
Filmarray Blood Culture Id (Bcid) Panel, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cobas%C2%AE+eplex+bcid+panels/filmarray+blood+culture+identification+panel/pmc08370220-103-11-10
Average 90 stars, based on 1 article reviews
filmarray blood culture id (bcid) panel - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
GenMark Diagnostics dx eplex blood culture id (bcid
Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of <t>ePlex</t> <t>BCID</t> panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).
Dx Eplex Blood Culture Id (Bcid, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cobas%C2%AE+eplex+bcid+panels/eplex+blood+culture+panels/pmc08370220-39-18-17
Average 90 stars, based on 1 article reviews
dx eplex blood culture id (bcid - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
GenMark Diagnostics eplex blood culture identification gram-positive panel
Turnaround time and pathogen targets of FDA-cleared multiplex <t> blood culture identification </t> panels
Eplex Blood Culture Identification Gram Positive Panel, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cobas%C2%AE+eplex+bcid+panels/dx+eplex+blood+culture+identification+gram+negative++bcid+gn++panel/pmc07431065-124-58-61
Average 90 stars, based on 1 article reviews
eplex blood culture identification gram-positive panel - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Accelerate Diagnostics phenotest bc kit
Turnaround time and pathogen targets of FDA-cleared multiplex blood culture identification panels
Phenotest Bc Kit, supplied by Accelerate Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cobas%C2%AE+eplex+bcid+panels/phenotest+bc+kit/pmc07431065-124-42-45
Average 90 stars, based on 1 article reviews
phenotest bc kit - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
GenMark Diagnostics eplex
Turnaround time and pathogen targets of FDA-cleared multiplex blood culture identification panels
Eplex, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cobas%C2%AE+eplex+bcid+panels/eplex/pmc08684256-246-45-44
Average 90 stars, based on 1 article reviews
eplex - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
GenMark Diagnostics eplex bcid-fp panel
Summary of CDC algorithm ([ <xref ref-type= 32 ], modified)." width="250" height="auto" />
Eplex Bcid Fp Panel, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cobas%C2%AE+eplex+bcid+panels/eplex+bcid+panels/pmc10532978-12-1-0
Average 90 stars, based on 1 article reviews
eplex bcid-fp panel - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
GenMark Diagnostics eplex bcid-fp
Summary of CDC algorithm ([ <xref ref-type= 32 ], modified)." width="250" height="auto" />
Eplex Bcid Fp, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cobas%C2%AE+eplex+bcid+panels/eplex+bcid+fp/10__1128_slash_jcm__02096___19-48-1-0
Average 90 stars, based on 1 article reviews
eplex bcid-fp - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
GenMark Diagnostics dx eplex bcid-gp panel cartridge
Summary of CDC algorithm ([ <xref ref-type= 32 ], modified)." width="250" height="auto" />
Dx Eplex Bcid Gp Panel Cartridge, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cobas%C2%AE+eplex+bcid+panels/dx+iuo+bcid+gp+panel/10__1128_slash_jcm__01730___19-61-1-0
Average 90 stars, based on 1 article reviews
dx eplex bcid-gp panel cartridge - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
BioFire Defense biofire filmarray bcid2
Summary of CDC algorithm ([ <xref ref-type= 32 ], modified)." width="250" height="auto" />
Biofire Filmarray Bcid2, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cobas%C2%AE+eplex+bcid+panels/bcid2+panel/pm39857024-147-17-17
Average 90 stars, based on 1 article reviews
biofire filmarray bcid2 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
GenMark Diagnostics eplex bcid
Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of <t>ePlex</t> <t>BCID</t> panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).
Eplex Bcid, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cobas%C2%AE+eplex+bcid+panels/eplex+bcid/pmc08370220-111-5-4
Average 90 stars, based on 1 article reviews
eplex bcid - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Commercial molecular assays.

Journal: Diagnostics

Article Title: Current Updates on Molecular Diagnostic Assays Used for Detection of Candida auris : A Systematic Review

doi: 10.3390/diagnostics15020140

Figure Lengend Snippet: Commercial molecular assays.

Article Snippet: Cobas ePlex BCID-FP (GenMark Dx, (Roche Diagnostics, Indianapolis, IN, USA)) , Multiplex PCR , Positive blood culture (contrived) , 49 , FDA-cleared , cobas ePlex system (Roche Diagnostics, Indianapolis, IN, USA) , Sensitivity: 100%; Specificity: 100%; LoD:/; Reference method: culture , [ ] .

Techniques: Real-time Polymerase Chain Reaction, Multiplex Assay, DNA Extraction

Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

Article Snippet: Recently, the ePlex BCID RUO panels were compared to the BioFire FilmArray blood culture ID (BCID) panel in 137 clinical blood cultures ( ).

Techniques: Comparison

Comparison of RDT platforms

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Comparison of RDT platforms

Article Snippet: Recently, the ePlex BCID RUO panels were compared to the BioFire FilmArray blood culture ID (BCID) panel in 137 clinical blood cultures ( ).

Techniques: Comparison, Bacteria

Comparison of RDT platforms

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Comparison of RDT platforms

Article Snippet: Recently, the ePlex BCID RUO panels were compared to the BioFire FilmArray blood culture ID (BCID) panel in 137 clinical blood cultures ( ).

Techniques:

Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

Article Snippet: An observational study was performed at University of Maryland Medical System comparing Verigene blood culture (BC) to GenMark Dx ePlex blood culture ID (BCID) (research use only) panels on blood cultures from adult patients.

Techniques:

Comparison of RDT platforms

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Comparison of RDT platforms

Article Snippet: An observational study was performed at University of Maryland Medical System comparing Verigene blood culture (BC) to GenMark Dx ePlex blood culture ID (BCID) (research use only) panels on blood cultures from adult patients.

Techniques:

Turnaround time and pathogen targets of FDA-cleared multiplex  blood culture identification  panels

Journal: Missouri Medicine

Article Title: Updates on Rapid Diagnostic Tests in Infectious Diseases

doi:

Figure Lengend Snippet: Turnaround time and pathogen targets of FDA-cleared multiplex blood culture identification panels

Article Snippet: There are currently four FDA-cleared molecular multiplex assays for blood culture pathogen identification: FilmArray BCID panel (bioMérieux, Marcy l’Etoile, France), Verigene Gram Positive Blood Culture ID assay (BCID-GP) and Gram Negative Blood Culture ID assay (BCID-GN) (Luminex Molecular Diagnostics, Toronto, Canada), Accelerate PhenoTest BC kit (Accelerate Diagnostics, Tucson, AZ), and ePlex Blood Culture Identification Gram-Positive Panel (BCID-GP) and Gram-Negative Panel (BCID-GN) (GenMark Diagnostics, Carlsbad, CA).

Techniques: Multiplex Assay, Bla VIM Assay

Turnaround time and pathogen targets of FDA-cleared multiplex blood culture identification panels

Journal: Missouri Medicine

Article Title: Updates on Rapid Diagnostic Tests in Infectious Diseases

doi:

Figure Lengend Snippet: Turnaround time and pathogen targets of FDA-cleared multiplex blood culture identification panels

Article Snippet: There are currently four FDA-cleared molecular multiplex assays for blood culture pathogen identification: FilmArray BCID panel (bioMérieux, Marcy l’Etoile, France), Verigene Gram Positive Blood Culture ID assay (BCID-GP) and Gram Negative Blood Culture ID assay (BCID-GN) (Luminex Molecular Diagnostics, Toronto, Canada), Accelerate PhenoTest BC kit (Accelerate Diagnostics, Tucson, AZ), and ePlex Blood Culture Identification Gram-Positive Panel (BCID-GP) and Gram-Negative Panel (BCID-GN) (GenMark Diagnostics, Carlsbad, CA).

Techniques: Multiplex Assay, Bla VIM Assay

Summary of CDC algorithm ([ <xref ref-type= 32 ], modified)." width="100%" height="100%">

Journal: Journal of Fungi

Article Title: An Overview on Candida auris in Healthcare Settings

doi: 10.3390/jof9090913

Figure Lengend Snippet: Summary of CDC algorithm ([ 32 ], modified).

Article Snippet: GenMark ePlex BCID-FP Panel , , Yes , n/a.

Techniques: Modification, Software

Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

Article Snippet: In this study, the GenMark ePlex BCID had a higher mean DOOR-MAT score due to the expanded number of targets identified.

Techniques:

Comparison of RDT platforms

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Comparison of RDT platforms

Article Snippet: In this study, the GenMark ePlex BCID had a higher mean DOOR-MAT score due to the expanded number of targets identified.

Techniques: